Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Helix BioPharma ( (TSE:HBP) ) has shared an update.
Helix BioPharma Corp. has postponed its Annual General and Special Meeting to March 26, 2025, to allow more time for shareholder approval on significant asset acquisitions from Laevoroc Immunology AG and Laevoroc Chemotherapy AG, along with a proposed financing strategy. This extension, supported by the Toronto Stock Exchange and pending a court application, highlights Helix’s strategic efforts to enhance its operational capabilities and financial structure, which could potentially strengthen its position in the oncology sector.
More about Helix BioPharma
Helix BioPharma Corp. is a clinical-stage oncology company focused on developing treatments for hard-to-treat cancers. The company operates in the biotechnology industry, with a market focus on innovative cancer therapies.
YTD Price Performance: 10.11%
Average Trading Volume: 5,308
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$51.96M
For a thorough assessment of HBP stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money